Raziel Therapeutics
Latest round
- Series C
Last raised
- Dec 2024
Total raised
- $22M
Investors
- 6
About Raziel Therapeutics
Founded in 2012 and based in Jerusalem, Israel, Raziel Therapeutics Ltd. is a pharmaceutical company that develops drugs for the treatment of obesity and related indications. The company's product, the RZL-012, causes fat cell death at the injection site which results in reduction of fat tissues.
Who invested in Raziel Therapeutics
6 investors across 2 rounds
See all investors in Raziel Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Raziel Therapeutics
Who invested in Raziel Therapeutics?
Raziel Therapeutics has 6 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Raziel Therapeutics raised?
Raziel Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Raziel Therapeutics last raise money?
Raziel Therapeutics's most recent round on record is a Series C, in Dec 2024.
What does Raziel Therapeutics do?
Founded in 2012 and based in Jerusalem, Israel, Raziel Therapeutics Ltd.
Where is Raziel Therapeutics headquartered?
Raziel Therapeutics is headquartered in Jerusalem, Israel.
Which VCs invest in companies like Raziel Therapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at Raziel Therapeutics's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like Raziel Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.